e-learning
resources
Stockholm 2002
Monday 16.09.2002
COPD - general -3
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation
L. Corkovic, N. Kostic, D. Begovic, L. Nagorni-Obradovic, S. Ignjatovic (Belgrade, Kragujevac, Yugoslavia)
Source:
Annual Congress 2002 - COPD - general -3
Session:
COPD - general -3
Session type:
Thematic Poster Session
Number:
1665
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Corkovic, N. Kostic, D. Begovic, L. Nagorni-Obradovic, S. Ignjatovic (Belgrade, Kragujevac, Yugoslavia). Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation. Eur Respir J 2002; 20: Suppl. 38, 1665
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 37s
Year: 2006
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation
Source: Eur Respir J 2001; 18: Suppl. 33, 483s
Year: 2001
Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis
Source: Eur Respir J 2004; 24: 958-963
Year: 2004
Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 583s
Year: 2005
Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers
Source: Eur Respir J 2002; 20: Suppl. 38, 88s
Year: 2002
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 128s
Year: 2004
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance
Source: Eur Respir J 2006; 28: Suppl. 50, 430s
Year: 2006
Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients
Source: Annual Congress 2007 - Cell biology of asthma and COPD
Year: 2007
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Sputum Vitamin D binding protein (VDBP) GC1S/1S genotype predicts airway obstruction: a prospective study in smokers with COPD
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report
Source: Eur Respir J 2003; 22: Suppl. 45, 70s
Year: 2003
Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Vitamin D and cathelicidin serum levels in children with infection induced asthma
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017
Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
Serum vitamin D levels and exercise-induced bronchoconstriction in children with asthma
Source: Eur Respir J 2011; 37: 1366-1370
Year: 2011
Serum leptin and neuropeptide Y levels in asthmatic and cystic fibrosis children
Source: Eur Respir J 2003; 22: Suppl. 45, 400s
Year: 2003
Serum surfactant protein D (SPD) as a specific marker for COPD
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept